Trial reportBrain communications2025
Soluble guanylate cyclase induces cranial vasodilation and headache in adults: a randomized trial.
Trial report in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oxytocin receptor antagonism in migraine: a randomized, double-blind, placebo-controlled provocation study.The journal of headache and pain · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of cranial vasodilation in headache pathogenesis sparks ongoing debate. Soluble guanylate cyclase is an enzyme that catalyses the conversion of guanosine triphosphate to cyclic guanosine monophosphate, leading to relaxation of vascular smooth muscle cells. Activation of this pathway might contribute to headache pathogenesis. We evaluated whether oral ingestion of riociguat, a stimulator of soluble guanylate cyclase, could elicit cranial vasodilation and headache in healthy adults. In this randomized, double-blind, placebo-controlled, two-way crossover study, we enrolled 12 healthy adults (nine females, three males; mean age 27.3 (SD 7.8) years). The participants attended two experimental sessions at a single site in Denmark (Danish Headache Center, Rigshospitalet, Denmark), receiving either a single oral dose riociguat 2.5 mg or placebo. The baseline measurements included the diameter of the superficial temporal artery and the blood flow velocity of the middle cerebral artery. These measurements were repeated over a 240-minute period after ingestion. The participants recorded headache occurrence and associated features in a diary for 12 h post-ingestion. For primary outcome (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.